Supplementary Figure S2 from Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Fig.S2: nucleofection of anti-CD20 CAR mRNA does not affect the expression of endogenous receptors on exPBNK cells PBNK cells were expanded ex vivo by co-culturing PBMC with irradiated geK562 feeder cell lines in the presence of 40 IU/mL IL-2 for 14 days and isolated by depleting CD3+ T cells. The expanded NK cells were nucleofected with anti-CD20 CAR mRNA (CAR) or without anti-CD20 CAR mRNA (mock). CAR exPBNK or MOCK exPBNK cells were stained with indicated monoclonal antibodies. The expression of receptors on viable exPBNK Cells were compared by flow cytometry analysis.
Authors: Yaya Chu, Jessica Hochberg, Ashlin Yahr, Janet Ayello, Carmella van de Ven, Matthew Barth, Myron Czuczman, Mitchell S. Cairo
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362532105